Jardiance Patient Assistance for Low-Income: How to Get Empagliflozin Affordable

Why Jardiance Costs So Much Without Help

Empagliflozin remains under patent protection with no FDA-approved generic version available in 2026. That single factor keeps the wholesale acquisition cost (WAC) high and leaves uninsured patients facing the full retail price, which averages around $680 for a 30-day supply of 10 mg or 25 mg tablets. Even insured patients routinely see Tier 3 or non-preferred brand copays of $50 to $150 per month, depending on the plan formulary.

The Patent Timeline

Boehringer Ingelheim holds composition-of-matter patents on empagliflozin that extend through the late 2020s. Several ANDA filers have challenged these patents, but no tentative FDA approval for a generic has been granted. Until generic entry occurs, the brand-only market keeps prices elevated.

How Insurance Tier Placement Affects You

Most commercial plans and Medicare Part D formularies place Jardiance on a preferred or non-preferred brand tier. A 2023 analysis of Medicare Part D plans found that empagliflozin appeared on the formulary of over 90% of standalone PDPs, but tier placement varied widely [1]. Plans that classify it as non-preferred brand may require prior authorization or step therapy through metformin first.

The practical result: your out-of-pocket cost depends less on the drug's list price and more on where your specific plan places it.

Boehringer Ingelheim Patient Assistance Program

The Boehringer Ingelheim Cares Foundation operates the primary PAP for Jardiance. This program supplies the medication at no cost to qualifying patients. It is one of the more generous manufacturer programs in the SGLT2 inhibitor class.

Who Qualifies

Eligibility requires meeting all three criteria. First, the patient must be a U.S. Resident. Second, household income must fall at or below 400% of the federal poverty level (FPL), which in 2026 equals approximately $62,400 for a single-person household or $129,600 for a family of four. Third, the patient must lack prescription drug coverage that would cover empagliflozin, or face a coverage gap that makes the medication unaffordable.

Medicare Part D enrollees in the coverage gap ("donut hole") may also qualify under certain conditions. Patients with Medicaid or VA benefits are generally excluded because those programs already provide coverage.

How to Apply

Applications require a prescriber's signature and documentation of income (tax return, pay stubs, or a signed attestation). The turnaround from submission to first medication shipment is typically 4 to 6 weeks. Approvals last 12 months and can be renewed annually.

Patients can apply online through the Boehringer Ingelheim Cares Foundation portal, by fax, or by mail. The prescribing physician's office handles most submissions. Some clinic social workers and patient navigators maintain pre-filled templates that speed the process considerably.

What You Receive

Approved patients receive a 90-day supply of Jardiance shipped directly to their home or physician's office. Refills ship automatically for the duration of the approval period, removing the burden of monthly pharmacy visits.

The Jardiance Savings Card

For patients with commercial (employer-sponsored or ACA marketplace) insurance, Boehringer Ingelheim offers the Jardiance Savings Card. This is separate from the PAP and targets a different population: insured patients whose copay or coinsurance remains too high.

How the Savings Card Works

Eligible patients can pay as little as $10 per fill for a 30-day or 90-day supply. The card covers the difference between $10 and the patient's actual copay, up to a maximum annual benefit. In 2025 and 2026, the annual cap has been set at $2,500 for most patients, though Boehringer Ingelheim adjusts this periodically.

Eligibility Restrictions

The savings card excludes patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state-funded healthcare program. This is a legal requirement under the federal Anti-Kickback Statute and the OIG guidance on manufacturer copay coupons [2]. Patients covered by an employer plan, an ACA marketplace plan, or a private individual plan generally qualify.

Activation and Renewal

Patients can activate the card online or by calling the number printed on it. The card links to the patient's pharmacy profile and applies automatically at the point of sale. Most cards expire at the end of each calendar year and must be re-activated.

Medicare Part D and the $2,000 Cap

The Inflation Reduction Act (IRA) restructured Medicare Part D cost-sharing beginning in 2025. The annual out-of-pocket spending cap is now $2,000, replacing the previous catastrophic threshold that could exceed $7,000 [3]. This change has a direct, measurable impact on Jardiance affordability for Medicare enrollees.

How the Cap Applies to Jardiance

A Medicare beneficiary paying a non-preferred brand copay of $100 per month for Jardiance would reach the $2,000 cap within 20 months, at which point the plan covers the remaining fills at no additional cost. Under the old structure, the same patient would have paid substantially more before reaching catastrophic coverage.

Medicare Extra Help (Low-Income Subsidy)

Medicare's Extra Help program (also called the Low-Income Subsidy, or LIS) reduces Part D premiums, deductibles, and copays for beneficiaries with limited income and assets [4]. Full-subsidy beneficiaries pay $0 for drugs below the federal poverty level threshold, or $4.50 for generic and $11.20 for brand-name drugs in 2026.

To qualify for full Extra Help in 2026, a single individual must have an annual income below approximately $22,590 and countable assets below $17,220 (excluding a home and one vehicle). Married couples filing jointly face limits of roughly $30,660 in income and $34,360 in assets.

The Medicare Prescription Payment Plan

Starting in 2025, Medicare Part D also introduced an optional monthly payment plan that spreads out-of-pocket costs evenly across the year. A patient expecting $1,200 in annual Part D spending on Jardiance could pay $100 per month instead of facing a large upfront cost in January and February when the deductible applies [3].

State Pharmaceutical Assistance Programs (SPAPs)

At least 23 states operate their own pharmaceutical assistance programs that supplement federal coverage. These SPAPs vary widely in eligibility criteria, covered drugs, and benefit levels.

Notable State Programs

New York's EPIC (Elderly Pharmaceutical Insurance Coverage) program covers Part D cost-sharing for residents aged 65 and older with incomes up to $75,000 (single) or $100,000 (married). Pennsylvania's PACE and PACENET programs serve residents 65 and older with incomes up to $14,500 and $23,500 respectively. New Jersey's PAAD covers Part D copays for residents with incomes below $27,234 (single) [5].

How SPAPs Interact with Part D

SPAP payments count toward a patient's true out-of-pocket (TrOOP) spending under Part D. This means SPAP assistance helps a patient reach the $2,000 cap faster, creating a compounding benefit.

Patients should check their state health department website or call their State Health Insurance Assistance Program (SHIP) for current eligibility details.

Pharmacy-Level Discount Strategies

Beyond manufacturer and government programs, several pharmacy-level strategies can reduce the effective price of Jardiance.

Discount Cards and Coupons

Third-party discount platforms such as GoodRx, RxSaver, and SingleCare negotiate prices with pharmacies and may offer Jardiance at $550 to $620 per month, a modest but real reduction from the $680 average cash price. These tools work best for uninsured patients who do not qualify for the PAP.

Mail-Order and 90-Day Fills

Many insurance plans offer lower per-unit costs for 90-day fills through mail-order pharmacies. A 90-day supply often costs the equivalent of two monthly copays rather than three. For Jardiance, this can save $50 to $150 per quarter depending on the plan's tiered pricing.

340B Program Pharmacies

Federally qualified health centers (FQHCs), disproportionate share hospitals, and other 340B-covered entities purchase outpatient drugs at steep discounts. Patients who receive care at a 340B-eligible clinic may access Jardiance at prices well below standard retail. The Health Resources and Services Administration (HRSA) maintains a searchable database of 340B-covered entities [6].

Insurance Coverage Field for Jardiance

Empagliflozin carries three FDA-approved indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD) at risk of progression [7]. This broad label expands insurance coverage pathways but also introduces variation in how plans handle authorization.

Commercial Plans

Most large employer plans cover Jardiance without prior authorization for the type 2 diabetes indication. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among type 2 diabetes patients with established cardiovascular disease treated with empagliflozin versus placebo [8]. This cardiovascular mortality benefit led the American Diabetes Association (ADA) to recommend SGLT2 inhibitors as preferred second-line agents for patients with atherosclerotic cardiovascular disease or heart failure [9].

For heart failure and CKD indications, some plans require documentation of ejection fraction (for HFrEF) or eGFR range (for CKD) before approving coverage.

Medicare Advantage and Part D

Medicare Advantage (MA) plans with integrated Part D benefits generally cover Jardiance. The 2025 IRA reforms have made these plans more predictable in terms of patient cost exposure. However, tier placement and prior authorization requirements still differ across MA plans.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has noted: "SGLT2 inhibitors like empagliflozin have moved from being considered add-on diabetes therapies to being recommended based on their cardiovascular and renal benefits, independent of glucose control" [9].

Navigating a Prior Authorization Denial

If a plan denies coverage for Jardiance, patients and prescribers can appeal. The most effective appeals cite the relevant clinical trial data, the ADA Standards of Care recommendation, and any documented intolerance or failure of formulary alternatives. Internal appeals typically take 30 to 60 days. External (independent) review is available in all 50 states for commercially insured patients.

Comparing SGLT2 Inhibitor Access Programs

Jardiance is not the only SGLT2 inhibitor with strong patient assistance. Understanding how its programs compare to competitors helps patients and prescribers make informed choices.

Jardiance vs. Farxiga (Dapagliflozin)

AstraZeneca offers a similar savings card for Farxiga with copays as low as $0 for commercially insured patients. The Farxiga PAP mirrors the Boehringer Ingelheim program in structure, with income thresholds at 400% FPL. From a clinical standpoint, the DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo [10]. Both drugs hold FDA approval for heart failure and CKD, so the access program comparison often matters as much as the clinical data when choosing between them.

Jardiance vs. Invokana (Canagliflozin)

Janssen's canagliflozin savings program has been less consistent, and the drug's narrower clinical profile (the CANVAS trial raised amputation risk concerns) may limit formulary placement in some plans [11]. For most patients, Jardiance or Farxiga represent the preferred access pathway within the SGLT2 class.

Step-by-Step: Getting Jardiance at the Lowest Possible Cost

The path to affordable Jardiance depends on your insurance status. Here is a practical decision framework.

If You Are Uninsured

1. Apply to the Boehringer Ingelheim Cares Foundation PAP through your prescriber.
2. While waiting for PAP approval (4 to 6 weeks), use a GoodRx or RxSaver coupon at a local pharmacy to reduce the cash price.
3. Ask your prescriber if a 340B pharmacy is available in your area.
4. If your income is low enough, apply for Medicaid. All 50 states plus DC now cover SGLT2 inhibitors on their preferred drug lists, though prior authorization requirements vary.

If You Have Commercial Insurance

1. Activate the Jardiance Savings Card to reduce your copay to as low as $10 per month.
2. Request a 90-day mail-order fill to cut per-unit costs.
3. If your plan places Jardiance on a non-preferred tier, ask your prescriber to submit a formulary exception request citing the ADA Standards of Care and the EMPA-REG OUTCOME data.

If You Have Medicare

1. Check whether you qualify for Medicare Extra Help (LIS). Call 1-800-MEDICARE or visit ssa.gov.
2. Enroll in the Medicare Prescription Payment Plan to spread costs monthly.
3. Check your state for an SPAP that supplements Part D.
4. Track your spending against the $2,000 annual cap. Once reached, your remaining fills cost $0.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the combined risk of cardiovascular death or heart failure hospitalization by 25% in patients with HFrEF, regardless of diabetes status [12]. This finding has expanded the clinical justification for insurance coverage beyond diabetes alone.

Dr. Milton Packer, a principal investigator of the EMPEROR trials, stated: "The benefits of empagliflozin in heart failure are consistent across the range of ejection fractions, making a strong case for broad access to this medication regardless of diabetes diagnosis" [12].

Common Mistakes That Increase Your Cost

Several avoidable errors lead patients to overpay for Jardiance.

Not Checking Plan Formulary Updates Annually

Insurance plans revise formularies every January. A drug that was Tier 2 last year may move to Tier 3 this year. Checking your plan's formulary each open enrollment season and switching plans if necessary can save hundreds of dollars annually.

Ignoring the Donut Hole Changes

Some Medicare patients still fear the coverage gap without realizing that the IRA's $2,000 cap has effectively eliminated the donut hole's financial sting. Understanding the new structure prevents unnecessary medication rationing.

Skipping the Savings Card Because You Have Insurance

The manufacturer savings card works on top of insurance, not instead of it. A patient with a $75 copay who activates the savings card pays $10 instead. The card covers the remaining $65. There is no reason to skip this step if you carry commercial coverage.

When Generic Empagliflozin May Arrive

Patent litigation under the Hatch-Waxman Act is ongoing. Several generic manufacturers have filed abbreviated new drug applications (ANDAs) with Paragraph IV certifications challenging Boehringer Ingelheim's patents. Based on patent expiry dates and typical litigation timelines, generic empagliflozin could enter the U.S. Market between 2028 and 2030. Generic entry typically reduces drug prices by 80% to 90% within 12 months of the first generic launch [13].

Until then, the programs described above represent the primary pathways to affordable access.